Amazon awarded patent for primary candidate to treat HIV

New York, Sept. 5 - Amazon Biotech, Inc. said it received a notice of allowance from the U.S. Patent and Trademark Office giving it protection for its investigative drug AMZ0026.

AMZ0026 is a therapeutic herbal composition and is Amazon's primary drug candidate. It is approved by the Food and Drug Administration for phase 1/2 studies in humans.

The drug has been shown to exhibit potential therapeutically beneficial effects on the immune system of immunodeficient HIV/AIDS patients, the New York-based plant pharmaceutical company said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.